Long non-coding RNA signature for predicting gastric cancer survival based on genomic instability

Abstract

Background: Gastric cancer is a prevalent type of tumor with a poor prognosis. Given the high occurrence of genomic instability in gastric cancer, it is essential to investigate the prognostic significance of genes associated with genomic instability in this disease. Methods: We identified genomic instability-related lncRNAs (GInLncRNAs) by analyzing somatic mutation and transcriptome profiles. We evaluated co-expression and enrichment using various analyses, including univariate COX analysis and LASSO regression. Based on these findings, we established an lncRNA signature associated with genomic instability, which we subsequently assessed for prognostic value, immune cell and checkpoint analysis, drug sensitivity, and external validation. Finally, PCR assay was used to verify the expression of key lncRNAs. Results: Our study resulted in the establishment of a seven-lncRNA prognostic signature, including PTENP1-AS, LINC00163, RP11-169F17.1, C8ORF87, RP11-389G6.3, LINCO1210, and RP11-115H13.1. This signature exhibited independent prognostic value and was associated with specific immune cells and checkpoints in gastric cancer. Additionally, the model was correlated with somatic mutation and several chemotherapeutic drugs. We further confirmed the prognostic value of LINC00163, which was included in our model, in an independent dataset. Our model demonstrated superior performance compared to other models. PCR showed that LINC00163 was significantly up-regulated in 4 adjacent normal tissues compared with the GC tissues. Conclusions: Our study resulted in the establishment of a seven-lncRNA signature associated with genomic instability, which demonstrated robust prognostic value in predicting the prognosis of gastric cancer. The signature also identified potential chemotherapeutic drugs, making it a valuable tool for clinical decision-making and medication use.

Analysis of multiple factors influencing the survival of patients with advanced gastric cancer

“…Gastric cancer is one of the most prevalent malignant neoplasms affecting the gastrointestinal system [ 1 ] and ranks as the fifth most common malignancy worldwide, following lung, breast, colorectal, and prostate cancers [ 2 ]. The current global ranking of gastric cancer-related deaths is fourth.…”

“…The current consensus is that surgery remains the primary curative approach for gastric cancer. With advancements in surgical technology and the integration of conventional radiotherapy, chemotherapy, and neoadjuvant therapy, the 5-year survival rate for patients with early-stage gastric cancer can reach an impressive 95% [ 1 ], while the 5-year survival rate of patients with advanced gastric cancer is a mere 20–60% [ 4 ]. Retrospective analysis of clinicopathological data from 120 patients with advanced gastric cancer admitted from 2014 to 2016 at Suqian Hospital Affiliated with Xuzhou Medical University was performed.…”